Shilpa Medicare Ltd

Shilpa Medicare Share Pledge

The company's promoters reported the release of encumbrance on 30,00,000 equity shares held by them. This reduction in pledged shares signals a change in promoter leverage.

Shilpa Medicare Other Announcement

Shilpa Medicare received a 'Crisil ESG 59' rating from CRISIL ESG Ratings for FY2026. This is a routine regulatory disclosure under Regulation 30 with no financial implications.

Shilpa Medicare Business Update

Shilpa Medicare reported a USFDA surveillance inspection at its Unit VII Analytical Services Division. The inspection resulted in one procedural observation with no material impact on operations.

Shilpa Medicare Regulatory Approval

Shilpa Medicare secured final CDSCO-SEC approval for OERIS™, a world-first extended-release ondansetron injection patented until 2039. Commercial launch in India is planned upon final marketing authorization.

Shilpa Medicare Annual General Meeting

Shilpa Medicare's 39th AGM held 11 September 2026 via VC. Resolutions covered financial statement adoption, ₹0.60/share dividend, and director re-appointment.

Shilpa Medicare Insolvency Petition

NCLT Ahmedabad admitted FTF Pharma, Shilpa Medicare's subsidiary, to CIRP over a ₹2.18 Crore debt. IRP appointed with moratorium; impact on parent unquantifiable.

Value

₹2.18 Cr

Shilpa Medicare Other Announcement

Shilpa Medicare has dispatched letters to shareholders with unregistered emails, providing web-links to access the Annual Report and Notice of the 39th Annual General Meeting.

Shilpa Medicare Price Movement Clarification

Shilpa Medicare clarified a news report regarding a voluntary recall of 27,923 vials of Pemetrexed Injection in the US. The company expects no material impact on operations.

Shilpa Medicare Annual Report

Shilpa Medicare Limited filed its Annual Report for the financial year 2025-26. The document also contains the notice convening the 39th Annual General Meeting.

Shilpa Medicare Annual General Meeting

Shilpa Medicare Limited has issued the notice for its 39th Annual General Meeting scheduled for September 11, 2026. The meeting will be held via video conferencing.

Shilpa Medicare Investor Presentation: Key Takeaways

Shilpa Medicare reported record Q1FY27 revenue of INR 469cr, up 43% YoY, with EBITDA margins hitting 30%. Strategy focuses on high-margin CDMO, Biologics, and complex formulations.

Shilpa Medicare Annual General Meeting

Shilpa Medicare Limited announced its Annual General Meeting on September 11, 2026. The agenda includes adopting financial statements and declaring a ₹0.60 per share dividend.

Shilpa Medicare Dividend

Shilpa Medicare Limited has fixed September 4, 2026, as the record date for final dividend entitlement. Payment is subject to shareholder approval at the upcoming September AGM.

Shilpa Medicare Q1 FY27 Results: Net Profit ₹100.9 Cr, Up 115.1% YoY

Shilpa Medicare Ltd reported revenue from operations of ₹465.8 Cr (+44.9% YoY) and net profit of ₹100.9 Cr (+115.1% YoY) for Q1 FY27.

Key figure

Net profit ₹100.9 Cr · +115.1% YoY

Shilpa Medicare Management Change

Shilpa Medicare appointed Dr. Uday N. Harle as CEO of its wholly owned subsidiary, Shilpa Biologicals Private Limited. The appointment is effective from August 3, 2026.

Shilpa Medicare Earnings Call Transcript: Key Takeaways

Shilpa Medicare delivered a robust Q4 performance with revenue growing 30% YoY, driven by API and formulation scale-ups, but remains heavily dependent on lumpy licensing income and future global clinical trial successes.

Shilpa Medicare Board Meeting Date

Shilpa Medicare scheduled a board meeting for August 5, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.

Shilpa Medicare Credit Rating

India Ratings assigned IND A+/Stable/IND A1+ ratings to Shilpa Biologicals' Rs 125 Crore bank facilities. This subsidiary rating reflects the group's credit profile.

Value

₹125.0 Cr

Shilpa Medicare Management Change

Dr. Sridevi Khambhampaty resigned as CEO of Shilpa Biologicals Private Limited, effective 15 July 2026. The resignation from the material subsidiary is due to personal commitments.

Shilpa Medicare Credit Rating

Shilpa Medicare's bank loan facilities were upgraded to IND AA- by India Ratings. The rating reflects improved creditworthiness, with a Stable Outlook.

Shilpa Medicare Board Meeting Outcome

Shilpa Medicare's board approved FY26 financials and a ₹0.60/share dividend. It also greenlit a ₹4.44 Crore investment in Neo Green Power for 28% equity.

Value

₹4.44 Cr

Shilpa Medicare Business Update

Shilpa Biologicals has entered a co‑development and supply agreement with Finland's Orion for a nivolumab biosimilar. The partnership expands Shilpa's European market footprint.

Shilpa Medicare Legal & Regulatory

Shilpa Biologicals settled a claim with Sartorius Stedim India for ₹9 Crore. The agreement was signed before the Commercial Court, Bengaluru.

Value

₹9.00 Cr

Shilpa Medicare Production Started

Shilpa Biologicals commissioned a state-of-the-art ADC GMP manufacturing facility, expanding its high‑potency biopharma capabilities. The facility is now operational, positioning the group as a CDMO partner.

Shilpa Medicare Capacity Expansion

Shilpa Biologicals commissioned a cutting‑edge ADC GMP manufacturing facility. The plant expands Shilpa Medicare’s CDMO capabilities for oncology drug substances.

Shilpa Medicare Acquisition Worth ₹63 Cr

Shilpa Medicare's subsidiary will invest €7 million (₹77 Crore) for a 30.4% stake in Gate2Brain. The partnership advances brain cancer therapies through strategic manufacturing and regulatory collaboration.

Value

₹63.00 Cr

Execution

Various tranches

Shilpa Medicare Business Update

Shilpa Medicare's Bengaluru facility concluded a USFDA inspection with five procedural observations. The company expects no material impact on operations and will respond within timelines.

Shilpa Medicare Other Announcement

Shilpa Medicare Limited filed its Annual Secretarial Compliance Report for the financial year 2025-26. The report confirms overall regulatory compliance with no material deviations or penalties.

Shilpa Medicare Earnings Call: Key Takeaways

Shilpa Medicare reported its highest-ever quarterly revenue of ₹439cr (+30% YoY) and full-year FY26 revenue of ₹1,549cr (+18% YoY), driven by API and formulation vertical integration.

Shilpa Medicare Earnings Call: Key Takeaways

Shilpa Medicare reported its highest-ever quarterly revenue and EBITDA, signaling a shift from a long investment cycle to asset sweating and operational leverage.